Recent clinical trials of immunotherapy in non-small-cell lung cancer

被引：7
|
作者：
Gkolfinopoulos, Stavros [1 ]
Mountzios, Giannis [2 ]
机构：
[1] BOC Oncol Ctr, Med Oncol Dept, CY-2006 Nicosia, Cyprus
[2] Henry Dunant Hosp Ctr, Med Oncol Dept 2, Athens 11526, Greece
来源：
IMMUNOTHERAPY | 2019年 / 11卷 / 06期
关键词：
atezolizumab; avelumab; checkpoint inhibitors; durvalumab; ipilimumab; nivolumab; non-small-cell lung cancer; pembrolizumab; DOCETAXEL; NIVOLUMAB; INTERLEUKIN-2; ATEZOLIZUMAB; BURDEN;
D O I：
10.2217/imt-2019-0021
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：461 / 466
页数：6
相关论文
共 50 条
  • [11] Potential role of immunotherapy in advanced non-small-cell lung cancer
    de Mello, Ramon Andrade
    Veloso, Ana Flavia
    Catarina, Paulo Esrom
    Nadine, Sara
    Antoniou, Georgios
    ONCOTARGETS AND THERAPY, 2017, 10 : 21 - 30
  • [12] Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice
    Rashdan, Sawsan
    Gerber, David E.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 202 - 207
  • [13] Immunotherapy in Small Cell Lung Cancer
    Esposito, Giovanna
    Palumbo, Giuliano
    Carillio, Guido
    Manzo, Anna
    Montanino, Agnese
    Sforza, Vincenzo
    Costanzo, Raffaele
    Sandomenico, Claudia
    La Manna, Carmine
    Martucci, Nicola
    La Rocca, Antonello
    De Luca, Giuseppe
    Piccirillo, Maria Carmela
    De Cecio, Rossella
    Botti, Gerardo
    Totaro, Giuseppe
    Muto, Paolo
    Picone, Carmine
    Normanno, Nicola
    Morabito, Alessandro
    CANCERS, 2020, 12 (09) : 1 - 17
  • [14] Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer
    Daly, Megan E.
    Monjazeb, Arta M.
    Kelly, Karen
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (12) : 1685 - 1693
  • [15] Duration of nivolumab for pretreated, advanced non-small-cell lung cancer
    Geier, Margaux
    Descourt, Renaud
    Corre, Romain
    Leveiller, Guillaume
    Lamy, Regine
    Goarant, Eric
    Bizec, Jean-Louis
    Bernier, Cyril
    Quere, Gilles
    Amrane, Karim
    Gaye, Elisabeth
    Lucia, Francois
    Burte, Emilie
    Chouaid, Christos
    Robinet, Gilles
    CANCER MEDICINE, 2020, 9 (19): : 6923 - 6932
  • [16] Durvalumab in non-small-cell lung cancer patients: current developments
    Mezquita, Laura
    Planchard, David
    FUTURE ONCOLOGY, 2018, 14 (03) : 205 - 222
  • [17] Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
    Lochrin, Sarah E.
    Forde, Patrick M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (08) : 415 - 423
  • [18] The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
    Xu, Yangyang
    Wang, Qin
    Xie, Jingyuan
    Chen, Mo
    Liu, Hongbing
    Zhan, Ping
    Lv, Tangfeng
    Song, Yong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [19] The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis
    Wang, Chengdi
    Qiao, Wenliang
    Jiang, Yuting
    Zhu, Min
    Shao, Jun
    Wang, Tao
    Liu, Dan
    Li, Weimin
    JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (05) : 4913 - 4927
  • [20] Immunotherapy for non-small-cell lung cancer
    Thomas, Anish
    Jakopovic, Marko
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (08) : 1061 - 1064
12345